Agonistic antibodies targeting TREM2 to shift microglia toward neuroprotective phenotype in Alzheimer's disease
🧪 Overview
TREM2 loss-of-function variants increase AD risk (~3-4x), and agonistic antibodies can enhance beneficial microglial responses including amyloid phagocytosis and plaque-associated microglial coverage. AL002 (Alector) in Phase 2 provides immediate clinical validation. Critical uncertainty remains regarding stage-dependency: TREM2 activation may benefit early amyloid phases but could worsen tau pathology or neuritic dystrophy in later disease stages. BBB penetration requires transporter-mediated delivery strategies.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |